UK-based epitaxial wafer and substrate provider IQE has reported that the overall market recovery is weaker than anticipated. As a result, the company expects its revenue for 2024 to remain flat compared to 2023. IQE also announced a strategic review...
The article requires paid subscription. Subscribe Now